CD274 and non-small cell lung carcinoma: It not only compared the effectiveness of first-line immune checkpoint inhibitors (ICIs) combined with chemotherapy in driver-gene negative advanced non-small cell lung cancer (NSCLC), but also conducted subgroup analyses based on patient characteristics such as age, gender, smoking status, pathology type, PD-L1 expression, organ metastasis, and specific drugs used.